On Tuesday, Dyne Therapeutics Inc. (NASDAQ:DYN) announced new clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) amenable to exon 51 ...
On Tuesday, Wave Life Sciences Ltd. (NASDAQ:WVE) revealed interim data from the ongoing Phase 2 FORWARD-53 study of WVE-N531 for Duchenne muscular dystrophy (DMD) patients amenable to exon 53 skipping ...
Duchenne therapy may be evolving from slowing disease to reversing it—with RNA approaches offering the prospect of restoring function. Ongoing research will determine if these advances can deliver ...
DMD is the result of mutations in the dystrophin gene located on the X chromosome. These mutations lead to the absence or dysfunction of the dystrophin protein, which is essential for muscle stability ...
Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are caused by mutations in the DMD gene, which reduces the amount of dystrophin, a protein that protects muscle fibers. DMD ...
As individuals age, maintaining muscular health becomes increasingly crucial, where the loss of muscle mass and strength is linked to a higher risk of falls and reduced physical activity. Now, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results